"The scale and scope we envision for Vir will allow us to fund targeted academic research, ramp our own research and development efforts, and write individual checks of up to $100 million to in-license innovative technology platforms and novel clinical assets from biotech and pharmaceutical companies."
Robert Nelsen, whose Arch Venture Partners is leading a $150 million investment, with additional funds coming from the Bill & Melinda Gates Foundation, in Vir Biotechnology Inc., a new enterprise pursuing infectious disease therapies

"Through high-intensity sequencing, population-scale clinical studies and unparalleled computing power, we hope to transform the paradigm from late-stage diagnosis and poor outcomes to early stage detection and more cancer cures. The indication of interest for this capital raise is a testament to investors' shared belief in our commitment."
Jeff Huber, CEO, Grail, an early cancer screening startup, which could raise more than $1 billion in a series B round, making it in one of the largest financings in med-tech history

"It wasn't an awful year, and there were still places where our indicators were up, but there were also a number of important numbers that were down."
Laura Vitez, life sciences deals analyst and manager of analytic propositions for Cortellis Competitive Intelligence, reporting on the deals space for 2016 at the J.P. Morgan Healthcare conference. In total, the number of 2016 biopharma deals eclipsed the previous year, by 130, but aggregate dollars were down 40 percent from 2015

"Reports of Exondys51's demise appear greatly exaggerated: first launch numbers promising."
From a research note by RBC Capital Markets analyst Simos Simeonidis, on the first full quarter of sales disclosed by Sarepta Therapeutics Inc. in an investor update. Net sales of Duchenne muscular dystrophy drug Exondys 51 (eteplirsen) were $5.4 million for 4Q16, higher than RBC's estimate of $2.7 million and consensus of $4.9 million